← Back to all trials
Active Not Recruiting
NCT03729778
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
Conditions: HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Sex: All
Ages: 21 Years – 75 Years
Healthy volunteers: Yes
Phase: EARLY_PHASE1
Enrollment: 100
Sponsor: VA Eastern Colorado Health Care System
Location: Rocky Mountain Regional VA Medical Center Aurora Colorado
Summary
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
Eligibility Criteria
Inclusion Criteria:
* Veterans only (accessibility to non-veterans pending)
* Age 21-45 or 55-75 Years Old
* Have not received pneumococcal vaccine Prevnar PCV-13
* Able to attend 2-3 study visits over 1 month
HIV+:
-Undetectable Viral load
HIV negative controls:
-no history or risks for HIV infection
Exclusion Criteria:
* Spleen removed
* Chronic Kidney disease (creatinine ≥ 2.0 mg/dL)
* Active liver disease
* Currently taking: Corticosteroids (prednisone, medrol, etc), Chemotherapy, Immunosuppressive medication (cyclosporine, methotrexate, azathioprine, infliximab, adalimumab, rituximab, etanercept, etc), or illicit drugs (methamphetamine, cocaine, crack, or heroin)
Source: ClinicalTrials.gov (NCT03729778). StuddyBuddy aggregates publicly available trial information.
